MoneyWorks4Me

Zydus Lifesciences - Quaterly Results

12 Aug 2026 Evaluate
A fair growth of 10.97% in the revenue at Rs. 28722.00 millions was reported in the June 2026 quarter as compared to Rs. 25883.00 millions during year-ago period.A slender decline of -11.72% was recorded to Rs. 3396.00  millions from Rs. 3847.00 millions in the corresponding previous quarter.Operating Profit reported a sharp decline to 7107.00 millions from 7425.00 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 28722.00 25883.00 10.97 28722.00 25883.00 10.97 114840.00 151163.00 -24.03
Other Income 1237.00 1571.00 -21.26 1237.00 1571.00 -21.26 28962.00 9058.00 219.74
PBIDT 7107.00 7425.00 -4.28 7107.00 7425.00 -4.28 55929.00 84325.00 -33.67
Interest 1031.00 1376.00 -25.07 1031.00 1376.00 -25.07 4829.00 4639.00 4.10
PBDT 6076.00 6049.00 0.45 6076.00 6049.00 0.45 49431.00 79686.00 -37.97
Depreciation 1519.00 1300.00 16.85 1519.00 1300.00 16.85 5612.00 5239.00 7.12
PBT 4557.00 4749.00 -4.04 4557.00 4749.00 -4.04 43819.00 74447.00 -41.14
TAX 1161.00 902.00 28.71 1161.00 902.00 28.71 8221.00 16698.00 -50.77
Deferred Tax -16.00 6.00 -366.67 -16.00 6.00 -366.67 -777.00 873.00 -189.00
PAT 3396.00 3847.00 -11.72 3396.00 3847.00 -11.72 35598.00 57749.00 -38.36
Equity 998.00 1006.00 -0.80 998.00 1006.00 -0.80 1006.00 1006.00 0.00
PBIDTM(%) 24.74 28.69 -13.74 24.74 28.69 -13.74 48.70 55.78 -12.70

Zydus Lifesciences Share Price

1199.55 19.55 (1.66%)
12-Aug-2026 11:15 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1935.90
Dr. Reddys Labs. 1200.25
Cipla 1465.80
Lupin 2258.30
Zydus Lifesciences 1199.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: